pharma · Age-related Macular Degeneration · Neovascular Age-related Macular Degeneration · OTLK
Outlook Therapeutics NL
Outlook Therapeutics NL B. V.
Outlook Therapeutics is a pharma organization headquartered in Cranbury, USA. It trades on NYSE under ticker OTLK. Primary therapeutic focus areas include Age-related Macular Degeneration, Neovascular Age-related Macular
Company details
- Status
- Public
- HQ
- Cranbury, USA
- Founded
- 2011
- Employees
- 59
- Programs
- 2
- Drugs
- 3
- Patents
- 2
Quick answer
Outlook Therapeutics is a pharma organization headquartered in Cranbury, USA. It trades on NYSE under ticker OTLK. Primary therapeutic focus areas include Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 2 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (2).
Company snapshot
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outloo
- 2 active pipeline program(s) linked via ClinicalTrials.gov.
- 2 US patent(s) indexed to this assignee profile.
- 2 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Outlook Therapeutics NL. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
This Week’s Biopharma News: New Approvals, Appeals, and AI
- approval
Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review
Recent coverage
Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review
Outlook Therapeutics has resubmitted its Biologics License Application (BLA) for LYTENAVA (bevacizumab-vikg) to the FDA, initiating a 60-day Class 1 review. This marks a critical step for the drug's potential approval in treating neovascular age-related macular degeneration (nAMD).
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- Phase 3
Active clinical programs
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Outlook Therapeutics NL.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Outlook Therapeutics NL.
- Clinical update
- Clinical update
- Patent grant
- Patent grant
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Outlook Therapeutics NL?
-
Is Outlook Therapeutics NL publicly traded?
-
What drugs does Outlook Therapeutics NL develop or market?
-
What are the latest developments for Outlook Therapeutics NL?
-
What therapeutic areas does Outlook Therapeutics NL focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.